Ultrahuman Raises $70 Million for Wearables and Health-Intelligence Research

A ring can collect a stream of measurements. Turning that stream into dependable health information is a separate engineering and research problem.

Ultrahuman’s 3 September announcement confirms a $70 million financing round involving Qualcomm Ventures, Labcorp and other investors. The company says the money will support sensing, AI, miniaturised electronics and clinical research.

Its stated direction is broader than a ring alone: connect continuous wearable signals with biochemical measurements and environmental information.

Different measurements, different roles

The company distinguishes Blood Vision, its blood-biomarker offering, from Ultrahuman Home, which measures the surrounding environment. Glucose monitoring adds another stream, while its Jade software is intended to connect the information.

Keeping those products distinct matters. A blood test, an environmental sensor and a wearable do not observe the same thing or carry interchangeable evidence.

The announcement also describes more computation and storage on Ring PRO. A specific chip platform or additional interaction features would need to be assessed against their own product documentation. The financing announcement alone does not establish those capabilities.

What the research shows—and what it does not

A peer-reviewed July study analysed cardiovascular fitness-age estimates in 442 Ultrahuman Ring users. It was a retrospective observational study, with authors affiliated to Ultrahuman.

The researchers examined associations between the estimate and lifestyle measures, including sleep and activity. They also explicitly addressed a methodological problem: relationships between an algorithm’s output and its own inputs can be partly circular.

That makes the distinction between independent correlates and built-in inputs valuable. It does not turn the study into an independent clinical trial showing that wearing the ring prevents disease, or that every health feature has been validated.

Why it matters

The relevant test is reproducibility: clearly defined measurements, appropriate reference methods, transparent study populations and evidence that holds outside the company’s initial cohorts. Those tests would make the platform’s outputs easier to assess as the product expands.

The financing’s technical significance will emerge from the work it enables. Investor participation is evidence of a financing decision, not a substitute for validation of a sensor, algorithm or health claim.

Sources

• Ultrahuman’s September 3 financing announcement
• Shanmugam and colleagues: cardiovascular fitness age in 442 adults

Image: Ultrahuman facility pictured in its financing announcement.